Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative octreotide for endoscopic resection of superficial duodenal epithelial tumors
jRCTs051230102Phase 2Active, not recruiting
- Start
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in Duodenal adenoma (DA), duodenal adenocarcinoma (DA), superficial nonampullary duodenal epithelial tumor (SNADET) and 1 more. Primary endpoints: Incidence of postoperative adverse events within 28 days after procedure (Cohort A) and Incidence of postoperative adverse events within 28 days after procedure (Cohort B). Started Oct 2023; status: active, not recruiting.
02
Drugs
octreotide
03
Conditions
Duodenal adenoma (DA)duodenal adenocarcinoma (DA)superficial nonampullary duodenal epithelial tumor (SNADET)ampullary adenocarcinoma
Beyond the preview
Go deeper on jRCTs051230102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230102.